Prothena Corporation plc $PRTA Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC decreased its holdings in shares of Prothena Corporation plc (NASDAQ:PRTA) by 28.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 51,941 shares of the biotechnology company’s stock after selling 20,618 shares during the period. SG Americas Securities LLC owned approximately 0.10% of Prothena worth $315,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Siren L.L.C. increased its position in Prothena by 16.7% in the 1st quarter. Siren L.L.C. now owns 1,283,555 shares of the biotechnology company’s stock valued at $15,884,000 after acquiring an additional 183,715 shares during the period. Purkiss Capital Advisors LLC grew its stake in shares of Prothena by 15.1% in the 2nd quarter. Purkiss Capital Advisors LLC now owns 24,904 shares of the biotechnology company’s stock valued at $151,000 after purchasing an additional 3,275 shares during the last quarter. Prospera Financial Services Inc acquired a new position in shares of Prothena in the second quarter valued at approximately $61,000. Public Employees Retirement System of Ohio acquired a new position in shares of Prothena in the second quarter valued at approximately $256,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of Prothena during the second quarter worth approximately $6,176,000. Hedge funds and other institutional investors own 97.08% of the company’s stock.

Analyst Upgrades and Downgrades

PRTA has been the topic of a number of analyst reports. Wall Street Zen upgraded shares of Prothena from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. UBS Group set a $36.00 target price on shares of Prothena in a report on Tuesday, October 28th. Chardan Capital raised shares of Prothena to a “strong-buy” rating in a report on Wednesday, November 19th. Piper Sandler raised their price objective on shares of Prothena from $15.00 to $36.00 and gave the company an “overweight” rating in a research report on Tuesday, October 28th. Finally, JMP Securities dropped their target price on Prothena from $29.00 to $11.00 and set a “market outperform” rating on the stock in a research report on Tuesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Prothena presently has a consensus rating of “Hold” and a consensus target price of $25.78.

Prothena Trading Up 3.0%

PRTA stock opened at $10.75 on Friday. The company’s 50-day moving average price is $10.12 and its 200 day moving average price is $8.00. Prothena Corporation plc has a 52 week low of $4.32 and a 52 week high of $17.66. The company has a market cap of $578.40 million, a P/E ratio of -1.91 and a beta of -0.09.

Prothena (NASDAQ:PRTA) last issued its earnings results on Thursday, November 6th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.07). The company had revenue of $2.42 million during the quarter, compared to analysts’ expectations of $6.64 million. Prothena had a negative net margin of 2,929.30% and a negative return on equity of 62.17%. On average, equities research analysts expect that Prothena Corporation plc will post -4.04 earnings per share for the current year.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.